Abstract
Introduction

Recent experimental and clinical studies have shown that bone marrow-derived cell therapy directly into the heart for myocardial infarction improves cardiac function and neovascularization (1-3). Mobilization of bone marrow cells into the peripheral blood by certain cytokines, such as granulocyte-colony stimulating factor (G-CSF), offers a noninvasive therapeutic strategy for the regeneration of the myocardium after myocardial infarction
. In addition to mobilization, G-CSF has been reported to promote survival of cardiac myocyte and prevent left ventricular remodeling after myocardial infarction (3, (6) (7) (8) (9) . Cardiac myocyte death occurs in end-stage heart failure and may contribute to myocardial dysfunction both in ischemic and dilated cardiomyopathy (10) , hence G-CSF is promising not only for the treatment of cardiac ischemia, but also for non-ischemic heart failure (11, 12) . (13, 14) . We 
Thromboangiitis obliterans (TAO), or Buerger's disease is a nonatherosclerotic, segmental vasculitis that most commonly affects the small and medium-sized vessels of the limb, but cardiac involvement is rare
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Case Report
A healthy 29- 
.5 mg/d); he was treated with ACE inhibitor from 24 weeks after G-CSF-mobilized PBMNC implantation. The level of plasma BNP further decreased from 66.3 pg/mL to 13.8 pg/mL, and the LVEF and the LV diameter in an echocardiogram normalized at 24 weeks after administration of ACE inhibitor; LVDd 52 mm, LVDs 40 mm, LVEF 46%, and FS 23%. Sustained improvements of ischemic limb symptoms such as rest pain and maximal walking distance continued up to 34 months in the follow-up period. The follow-up echocardiogram at 33 months after G-CSF-mobilized PBMNC implantation also showed sustained improvement, with LVDd 47 mm, LVDs 35 mm, LVEF 50%, and FS 26%.
Discussion
We reported a rare case of non-ischemic DCM in a patient with TAO. Not only his ischemic leg symptoms but also his cardiac functions monitored by the level of plasma BNP and MIBG scintigraphic parameters improved after G-CSF-mobilized PBMNC implantation on his ischemic leg. This is the first report of a case of non-ischemic DCM associated with TAO. The etiology of TAO is still uncertain; tobacco smoking is critical to its onset, progression and recurrence (13). Although some epidemiological studies have shown that tobacco smoking increases the risk of idiopathic DCM (16), a recent multi-hospital case-control study in Japan showed that the odds ratio of tobacco smoking under 20
per day for DCM is 1.09 (17) . Further, most TAO patients have a history of tobacco smoking, but cardiac complications, even coronary artery disease, are a rare complication of TAO (13, 14) . Immunological abnormalities may involve both TAO and DCM but the precise mechanism is still unknown (18, 19 (20, 21) . MIBG abnormalities are correlated with LVEF, New York Heart Association functional class, and histopathological abnormalities (22, 23) . Furthermore, MIBG abnormalities preceded deterioration in LVEF, and MIBG imaging reveals improvement before echocardiographic improvement, indicating that MIBG imaging is a more sensitive tool for monitoring cardiac functions (20, 24) . Abnormalities in cardiac sympathetic activity contribute to the progression of heart failure, and recent studies reported a potential role of MIBG scintigraphy in predicting the therapeutic response to medical treatments such as β-blocker or ACE inhibitor in patients with heart failure (25, 26 (3, 4, 7, 8) . G-CSF also protects cardiomyocytes and endothelial cells from apoptotic cell death (9 (27) . Three months after cell therapy, LV volumes decreased and LVEF increased, however, 10 months later, the beneficial effects of cell therapy were lost (27) . A recent clinical study showed that G-CSF administration improved physical performance not only for patients with ischemic cardiomyopathy but also for DCM (28 (29) . Furthermore, experimental data showed that the transfer of endothelial progenitor cells improved in attenuating myocardial damage in rats with DCM induced following myocarditis (30) .
Our report suggests that PBMNC implantation with G-CSF could be an effective approach to treating non-ischemic heart failure, though the exact mechanisms of the improved cardiac function are still unclear.
